Can Ventaris Surgical’s $30m-backed system solve the biggest gap in kidney stone treatment?
Ventaris Surgical raises $30M to advance its kidney stone treatment system. Find out how it could reshape ureteroscopy outcomes in 2026.
Why the Nanodropper–Bedo–Viseon merger could reset the rules of personalized eyecare
Mu Medical unites Nanodropper, Bedo, and Viseon into a precision eyecare platform. Find out what this could mean for the future of AI-led ophthalmology.
Why Princeton Radiology is betting on whole-body MRI and breast screening growth
Princeton Radiology acquires two centers from RAI—see how this move reshapes outpatient imaging strategy, tech, and patient services in New Jersey.
Labcorp and Quest partner with Visby to expand access to rapid at-home PCR STI test
Visby’s at-home PCR STI test now on Quest and Labcorp. Find out how this redefines women’s health diagnostics and access. Read the full analysis.
Can MRI body scans redefine preventive care? AMRA expands into Dutch market with Prescan
AMRA and Prescan launch a first-in-Netherlands MRI scan to assess fat and muscle composition. Learn how this could redefine early disease detection in Europe.
Welldoc seeks FDA nod for AI-based glucose prediction in non-insulin type 2 diabetes
Welldoc’s CGM-based glucose prediction tool for non-insulin users is now under FDA review. Find out what it could change in diabetes care.
Why Aetna’s pediatric telehealth play with Blueberry could redefine Medicaid access
Can Aetna’s new pediatric telehealth model with Blueberry cut ER visits and scale Medicaid care? Find out what this pilot means for future access.
Can Alessa’s Enolen implant change how early-stage prostate cancer is treated?
Alessa’s Enolen earns FDA fast track for localized prostate cancer. Find out how this implant could redefine early-stage treatment and challenge current norms.
PharmaJet’s needle-free system to power Scancell’s melanoma Phase 3 after strong DNA therapy data
PharmaJet’s needle-free device will deliver Scancell’s DNA immunotherapy in a Phase 3 melanoma trial. Find out what this means for the future of cancer vaccines.
Polyrizon names PL-14 allergy blocker NASARIX, positioning polymer-based nasal barrier for market readiness
Find out how Polyrizon’s NASARIX branding positions the PL-14 allergy blocker for regulatory progress and future market readiness.